Lupus erythematosus

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024
Magnetic resonance, Antigen presentation, Patient, Chronic obstructive pulmonary disease, IP, MRI, Inflammatory bowel disease, Pharmacokinetics, Rheumatoid arthritis, Asthma, Fatigue, Joint stiffness, IBD, API, HCQ, Cannabidiol, COPD, Quality of life, Plasma, NDA, FDA, Pain, Lupus erythematosus, Inflammation, Biomarker, Epilepsy, Magnetic resonance imaging, Hydroxychloroquine, Pharmaceutical industry

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata

Retrieved on: 
Wednesday, September 13, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Depression, Lupus erythematosus, Therapy, IL-7, Hair loss, Bio, Anxiety, TSLP, Pathology, Quality of life, Woman, Atopic dermatitis, Alopecia areata, Incidence, Hair, Patient, Immune system, Disease, Autoimmunity, Inflammation, Pharmaceutical industry

Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.

Key Points: 
  • Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.
  • Q32 Bio and Horizon are collaborating to develop bempikibart, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.
  • Thompson, Ph.D., executive vice president, research and development, Horizon.
  • Bempikibart has the potential to provide long-term, durable improvement in hair loss, including the potential for disease remittance,” added Jason Campagna, M.D., Ph.D., chief medical officer, Q32 Bio.

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata

Retrieved on: 
Tuesday, May 17, 2022
Pharmaceutical, Genetics, Health, Clinical Trials, Christian democracy, Nasdaq, Degenerative disease, Patient, Â, Hair, Cell, Depression, SALT, Week, Alopecia areata, Anxiety, ILT7, Lupus erythematosus, Hair loss, Pharmaceutical industry

The primary endpoint is the percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 24.

Key Points: 
  • The primary endpoint is the percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 24.
  • This endpoint is a well-validated metric and widely utilized tool for determining the degree of hair loss and regrowth4.
  • SALT scores are measured on a scale from 1 to 100, with 1 representing no hair loss and 100 representing total hair loss.
  • Horizon is also investigating daxdilimab in systemic lupus erythematosus and plans to investigate it in dermatomyositis, discoid lupus erythematosus and lupus nephritis.

CHEMISTRY Rx Receives ACHC Accreditation as Pharmacy for Rare Diseases and Orphan Drugs

Retrieved on: 
Thursday, January 13, 2022
Patient, Lupus erythematosus, Specialty pharmacy, Accreditation, ACHC, Degenerative disease, Lists of diseases, Mean anomaly, Skin, Pharmacist, Ichthyosis, National Association of Boards of Pharmacy, Disorder, Hair, Nail, Medicine, Pharmacy

PHILADELPHIA, Jan. 13, 2022 /PRNewswire/ -- We are extremely proud to announce that Chemistry Rx now also received ACHC accreditation as a pharmacy for Rare Diseases and Orphan Drugs.

Key Points: 
  • PHILADELPHIA, Jan. 13, 2022 /PRNewswire/ -- We are extremely proud to announce that Chemistry Rx now also received ACHC accreditation as a pharmacy for Rare Diseases and Orphan Drugs.
  • Chemistry Rx Pharmacy specializes in compounded and specialty medications for rare pediatric diseases and disorders of the skin, hair and nails in children and adults.
  • The ACHC Rare Diseases and Orphan Drugs distinction applies a rigorous set of specific accreditation standards to ensure that highest-quality, state-of-the-art care is provided to all patients who are affected by a rare disorder (any condition that affects less than 200,000 people in the US).
  • At Chemistry Rx, these standards are applied in addition to the full set of ACHC Specialty Pharmacy requirements.

Worldwide Photopheresis Products Industry to 2029 - Key Drivers, Challenges and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021
Biotechnology, Health, Medical Devices, Autoimmunity, Scleroderma, GVHD, T-cell lymphoma, US Foods, Incidence, ECP, Patient, Food, Atopic dermatitis, National Institute, NIEHS, Photopheresis, Death, Blood, CTL, Graft-versus-host disease, Lupus erythematosus, Research, Asia, National Institute of Environmental Health Sciences, Transplant, UVA, Autoimmune disease, Female, Crohn's disease, Degenerative disease, Population, Lichen planus, Government, Woman, Pharmaceutical industry, Vaccine

The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.

Key Points: 
  • The US Food and Drug Administration has approved photopheresis, commonly known as extracorporeal photopheresis (ECP), for the treatment of cutaneous T-cell lymphoma.
  • This report covers all the quantitative aspects of the Photopheresis Products Market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.
  • A rise in the number of organ transplant patients is predicted to increase the demand for photopheresis products.
  • However, on other hand, due to the high cost of ECP therapy, the global market for photopheresis products may experience a slowdown.

Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Cutaneous lupus erythematosus, Connective tissue diseases, Lupus, William Osler, Autoimmune disease, Sjögren syndrome, Lupus erythematosus

It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.

Key Points: 
  • It is the third U.S. FDA approval of a lupus therapy since 2011, expanding treatment options for this medically underserved and life-threatening autoimmune disease.
  • With the approval of Saphnelo, we now have one more drug that allows us to translate valuable research knowledge into clinical practice with multiple benefits for our patients with lupus."
  • Saphnelo showed benefits on overall lupus disease activity, skin lupus and joints and the ability to taper down steroid doses.
  • The Lupus Foundation of America's research during the 1980s contributed to the development of Saphnelo through its support of research on interferons.

Global Systemic Lupus Erythematosus Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Health, Other Health, Autoimmune diseases, Medical specialties, Clinical medicine, Connective tissue diseases, Medicine, Cutaneous lupus erythematosus, Lupus erythematosus, Lupus, Sjögren syndrome, Systemic, Acute cutaneous lupus erythematosus, Lupus Canada

b'The "Global Systemic Lupus Erythematosus Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Systemic Lupus Erythematosus Epidemiology and Patient Flow Analysis - 2021, provides Systemic Lupus Erythematosus epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Systemic Lupus Erythematosus Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Systemic Lupus Erythematosus Epidemiology and Patient Flow Analysis - 2021, provides Systemic Lupus Erythematosus epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Systemic Lupus Erythematosus patients, history of the disease at the population level (Systemic Lupus Erythematosus prevalence, Systemic Lupus Erythematosus incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSystemic Lupus Erythematosus patient flow: Systemic Lupus Erythematosus prevalence, diagnosed, and drug-treated patients\nDemographics: Systemic Lupus Erythematosus patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Systemic Lupus Erythematosus market sizing, assessing market potential, and developing drug forecast models\nIdentify Systemic Lupus Erythematosus patients segments through age groups, gender, and disease sub-types\nEvaluate Systemic Lupus Erythematosus market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005191/en/\n'

United States Systemic Lupus Erythematosus Market and Competitive Landscape Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 3, 2021
Pharmaceutical, Health, Other Health, Autoimmune diseases, Cutaneous lupus erythematosus, Medical specialties, Clinical medicine, Lupus erythematosus, Organ systems, Lupus, Systemic

The "US Systemic Lupus Erythematosus Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Systemic Lupus Erythematosus Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest research US Systemic Lupus Erythematosus Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Systemic Lupus Erythematosus pipeline products, Systemic Lupus Erythematosus epidemiology, Systemic Lupus Erythematosus market valuations and forecast, Systemic Lupus Erythematosus drugs sales and competitive landscape in the US.
  • Systemic Lupus Erythematosus pipeline: Find out the products in clinical trials for the treatment of Systemic Lupus Erythematosus by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Systemic Lupus Erythematosus drugs: Identify key products marketed and prescribed for Systemic Lupus Erythematosus in the US, including trade name, molecule name, and company
    Systemic Lupus Erythematosus drugs sales: Find out the sales revenues of Systemic Lupus Erythematosus drugs in the US
    Systemic Lupus Erythematosus market valuations: Find out the market size for Systemic Lupus Erythematosus drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Systemic Lupus Erythematosus drugs market share: Find out the market shares for key Systemic Lupus Erythematosus drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Systemic Lupus Erythematosus products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005749/en/

LRA Pleased to Share GSK's Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA

Retrieved on: 
Thursday, December 17, 2020
Medical specialties, Clinical medicine, Medicine, Kidney diseases, Autoimmune diseases, Monoclonal antibodies, Cutaneous lupus erythematosus, Lupus erythematosus, Nephritis, Lupus, Belimumab, Lupus and pregnancy

Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was first approved for systemic lupus erythematosus in 2011.

Key Points: 
  • Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was first approved for systemic lupus erythematosus in 2011.
  • "An effective treatment developed specifically for lupus nephritis has been desperately needed," commented Lupus Research Alliance President and CEO Kenneth M. Farber.
  • We at the LRA are thrilled to share this news about belimumab and look forward to future approvals of other lupus nephritis treatment options."
  • Five out of 10 adults with lupus will have lupus nephritis, while eight out of 10 children with lupus will have kidney damage, which usually stems from lupus nephritis.

Global Systemic Lupus Erythematosus (SLE) Drugs Market to 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 15, 2020
Health, Pharmaceutical, Autoimmune diseases, Medical specialties, Cutaneous lupus erythematosus, Clinical medicine, Organ systems, Lupus erythematosus, Lupus

The "Systemic Lupus Erythematosus (Sle) Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Lupus Erythematosus (Sle) Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Systemic Lupus Erythematosus (Sle) Drugs estimated at US$183.3 Million in the year 2020, is projected to reach a revised size of US$264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.
  • The U. S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 5% CAGR for the Period of 2020-2027
    The Systemic Lupus Erythematosus (Sle) Drugs market in the U. S. is estimated at US$54 Million in the year 2020.
  • China, the world second largest economy, is forecast to reach an estimated market size of US$46.6 Million in the year 2027 trailing a CAGR of 5% through 2027.